NON-NUCLEAR production of Medical Radioisotopes . . .
Posted: Fri May 14, 2021 8:51 amNorthStar Medical Radioisotopes Receives Electron Beam Accelerators for First-of-its-Kind Advanced Medical Radioisotope Production.
[ https://nuclear-news.net/2021/05/13/non ... tium-tc99/ ]
May 12, 2021
NO, nuclear lobby, a nuclear reactor is NOT the only, nor the best, way to produce medical Technetium TC99 « nuclear-news
NorthStar, leading the way as the sole U.S. commercial supplier of molybdenum-99 (Mo-99), continues expansion efforts for increased capacity and ongoing reliable supply for diagnostic imaging
BELOIT, Wis.--(BUSINESS WIRE), 12 May 21, --NorthStar Medical ... nuclear-news.net
NorthStar Medical Radioisotopes Receives Electron Beam Accelerators for First-of-its-Kind Advanced Medical Radioisotope Production.
NorthStar, leading the way as the sole U.S. commercial supplier of molybdenum-99 (Mo-99), continues expansion efforts for increased capacity and ongoing reliable supply for diagnostic imaging −BELOIT, Wis.–(BUSINESS WIRE), 12 May 2021, —
NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, announced that it has achieved a major milestone in its efforts to expand U.S. production capacity for the important medical radioisotope, molybdenum-99 (Mo-99). The Company has received two custom-built IBA Rhodotron®TT 300-HE (High Energy) electron beam accelerators at its facility in Beloit, Wisconsin. The accelerators are critical components in a first-of-its-kind commercial-scale process to produce Mo-99, the parent radioisotope of technetium-99m, the most widely used medical imaging radioisotope, informing healthcare decisions for approximately 40,000 U.S. patients daily.
NorthStar Medical Radioisotopes is the sole commercial U.S. producer of the important medical radioisotope Mo-99 and the only company in the world to use environmentally friendly Mo-99 production processes that are non-uranium based. For over two years, NorthStar has provided the United States with reliable Mo-99 supply, which is used in its RadioGenix® System (technetium Tc 99m generator) to produce Tc-99m. NorthStar is aggressively expanding and establishing dual production and processing hubs for additional Mo-99 capacity to better meet customer demand and to ensure reliable, sustainable U.S. supply. Two facility expansion projects are nearing completion in Beloit, Wisconsin, to augment current Mo-99 production and processing in Columbia, Missouri, conducted in partnership with the University of Missouri Research Reactor (MURR®). NorthStar’s Isotope Processing facility in Beloit will enable it to more than double its current Mo-99 processing and is nearing completion, with FDA approval anticipated in 2022. The Company’s Accelerator Production facility in Beloit will add significant Mo-99 capacity, enable flexible production scheduling and minimize customer supply risks.
Delivery of these electron beam accelerators to advance Mo-99 production marks a tremendous milestone event for NorthStar, nuclear medicine and the patients who rely on diagnostic imaging studies for their health,” said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes. “Using electron beam accelerators is one of the most efficient methods of producing Mo-99, and like other NorthStar processes, it is non-uranium based and environmentally friendly. This production method will increase capacity, provide additional production days, and minimize supply risks. Additionally, electron beam accelerators can be used to produce therapeutic radioisotopes such as actinium-225 and copper-67. We anticipate that testing of these accelerators will begin this year, with commercial accelerator production commencing in 2023, pending appropriate licensure and FDA approval.”……………
Delivery of these electron beam accelerators to advance Mo-99 production marks a tremendous milestone event for NorthStar, nuclear medicine and the patients who rely on diagnostic imaging studies for their health,” said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
“Using electron beam accelerators is one of the most efficient methods of producing Mo-99, and like other NorthStar processes, it is non-uranium based and environmentally friendly. This production method will increase capacity, provide additional production days, and minimize supply risks. Additionally, electron beam accelerators can be used to produce therapeutic radioisotopes such as actinium-225 and copper-67. We anticipate that testing of these accelerators will begin this year, with commercial accelerator production commencing in 2023, pending appropriate licensure and FDA approval.”….
[
https://www.businesswire.com/news/home/ ... 005048/en/ ]
[ https://nuclear-news.net/2021/05/13/non ... tium-tc99/ ]
May 12, 2021
NO, nuclear lobby, a nuclear reactor is NOT the only, nor the best, way to produce medical Technetium TC99 « nuclear-news
NorthStar, leading the way as the sole U.S. commercial supplier of molybdenum-99 (Mo-99), continues expansion efforts for increased capacity and ongoing reliable supply for diagnostic imaging
BELOIT, Wis.--(BUSINESS WIRE), 12 May 21, --NorthStar Medical ... nuclear-news.net
NorthStar Medical Radioisotopes Receives Electron Beam Accelerators for First-of-its-Kind Advanced Medical Radioisotope Production.
NorthStar, leading the way as the sole U.S. commercial supplier of molybdenum-99 (Mo-99), continues expansion efforts for increased capacity and ongoing reliable supply for diagnostic imaging −BELOIT, Wis.–(BUSINESS WIRE), 12 May 2021, —
NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, announced that it has achieved a major milestone in its efforts to expand U.S. production capacity for the important medical radioisotope, molybdenum-99 (Mo-99). The Company has received two custom-built IBA Rhodotron®TT 300-HE (High Energy) electron beam accelerators at its facility in Beloit, Wisconsin. The accelerators are critical components in a first-of-its-kind commercial-scale process to produce Mo-99, the parent radioisotope of technetium-99m, the most widely used medical imaging radioisotope, informing healthcare decisions for approximately 40,000 U.S. patients daily.
NorthStar Medical Radioisotopes is the sole commercial U.S. producer of the important medical radioisotope Mo-99 and the only company in the world to use environmentally friendly Mo-99 production processes that are non-uranium based. For over two years, NorthStar has provided the United States with reliable Mo-99 supply, which is used in its RadioGenix® System (technetium Tc 99m generator) to produce Tc-99m. NorthStar is aggressively expanding and establishing dual production and processing hubs for additional Mo-99 capacity to better meet customer demand and to ensure reliable, sustainable U.S. supply. Two facility expansion projects are nearing completion in Beloit, Wisconsin, to augment current Mo-99 production and processing in Columbia, Missouri, conducted in partnership with the University of Missouri Research Reactor (MURR®). NorthStar’s Isotope Processing facility in Beloit will enable it to more than double its current Mo-99 processing and is nearing completion, with FDA approval anticipated in 2022. The Company’s Accelerator Production facility in Beloit will add significant Mo-99 capacity, enable flexible production scheduling and minimize customer supply risks.
Delivery of these electron beam accelerators to advance Mo-99 production marks a tremendous milestone event for NorthStar, nuclear medicine and the patients who rely on diagnostic imaging studies for their health,” said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes. “Using electron beam accelerators is one of the most efficient methods of producing Mo-99, and like other NorthStar processes, it is non-uranium based and environmentally friendly. This production method will increase capacity, provide additional production days, and minimize supply risks. Additionally, electron beam accelerators can be used to produce therapeutic radioisotopes such as actinium-225 and copper-67. We anticipate that testing of these accelerators will begin this year, with commercial accelerator production commencing in 2023, pending appropriate licensure and FDA approval.”……………
Delivery of these electron beam accelerators to advance Mo-99 production marks a tremendous milestone event for NorthStar, nuclear medicine and the patients who rely on diagnostic imaging studies for their health,” said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
“Using electron beam accelerators is one of the most efficient methods of producing Mo-99, and like other NorthStar processes, it is non-uranium based and environmentally friendly. This production method will increase capacity, provide additional production days, and minimize supply risks. Additionally, electron beam accelerators can be used to produce therapeutic radioisotopes such as actinium-225 and copper-67. We anticipate that testing of these accelerators will begin this year, with commercial accelerator production commencing in 2023, pending appropriate licensure and FDA approval.”….
[
https://www.businesswire.com/news/home/ ... 005048/en/ ]